Where alcohol use disorder treatment is heading
Alcohol use disorder · Updated Nov 15, 2026
About 28 million Americans have alcohol use disorder, and fewer than 1 in 10 receive treatment. Approved medicines (naltrexone, acamprosate and disulfiram) work but are rarely prescribed; counseling, mutual-help groups and medical withdrawal care are the other pillars. Research is focused on GLP-1 drugs such as semaglutide, which appear to reduce the urge to drink, on psychedelic-assisted therapy, and on starting treatment where people already are, in hospitals and emergency rooms.
- 400studies open or running
- 19phase 3 trials
- 1,883papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
GLP-1 drugs reduce drinkingHappened 41.1 point drop in heavy drinking days
Three randomized trials found semaglutide reduced heavy drinking or craving; in the largest, heavy drinking days fell 41.1 points vs 26.4.
41.1: percentage-point drop in heavy drinking days, vs 26.4 with placebo.
Starting naltrexone in hospitalHappened 23.8% heavy drinking days at 3 months
Started at discharge, naltrexone pills or shots cut heavy drinking days from about 70% to about 25%.
23.8%: heavy drinking days after 3 months with the injection, from 70.7%.
Psilocybin shows early promiseHappened 2.78 odds ratio for abstinence
Across 6 small trials, psilocybin-assisted therapy reduced drinking and raised the odds of abstinence 2.78 times.
2.78: times higher odds of staying abstinent (odds ratio).
-
6 months
by May 2027
New targets for craving and sleepPossible
NIAAA tests apremilast for craving (due January 2027); a VA-linked trial tests suvorexant for sleep in AUD with PTSD (due March 2027).
-
12 months
by Nov 2027
Does CBD reduce drinking?Possible
A University of Colorado trial (180 people) compares two CBD products with placebo; due April 2027.
-
3 years
by late 2029
A Lilly drug in two phase 3 trialsPossible
Eli Lilly's RENEW-ALC-1 and -2 (2,200 people) test brenipatide, a weekly injection, against placebo for 56 weeks; due April 2028.
Semaglutide for veteransPossible 41.1 point drop in heavy drinking days
The VA CRAVE trial (622 veterans) tests semaglutide over 24 weeks; due March 2029.
41.1: percentage-point drop in heavy drinking days, vs 26.4 with placebo.
Treatment from the emergency roomPossible
A Yale trial (240 people) tests starting naltrexone in the emergency department; due August 2028.
-
5 years
by late 2031
Psychedelic-assisted therapy in phase 3Long shot 2.78 odds ratio for abstinence
A phase 3 trial in Nîmes, France, tests psilocybin to prevent relapse in AUD with depression (due June 2030); LSD and MDMA trials are also running.
2.78: times higher odds of staying abstinent (odds ratio).
A first new approved medicine in decadesLong shot
If the GLP-1-type trials succeed, a new class of AUD medicine could be submitted for approval.
The research paths
GLP-1 and gut-hormone drugs
41.1 point drop in heavy drinking daysDetails and 4 trialsHide
Semaglutide, tirzepatide and new weekly injections that may dampen the reward from alcohol.
WatchRENEW-ALC; CRAVE.
- Semaglutide in AUD with obesity (Copenhagen trial)
- Low-dose semaglutide trial (UNC)
- Oral semaglutide trial
- Brenipatide (RENEW-ALC-1)Eli Lilly · 1,100 people · enrolling Apr 2028
- Brenipatide (RENEW-ALC-2)Eli Lilly · 1,100 people · enrolling Apr 2028
- Semaglutide for veterans (CRAVE)US Department of Veterans Affairs · 622 people · enrolling Mar 2029
- Tirzepatide, AUD with schizophreniaCopenhagen (Fink-Jensen) · 108 people · enrolling Aug 2028
Psychedelic-assisted therapy
2.78 odds ratio for abstinenceDetails and 3 trialsHide
One or two guided sessions with psilocybin, LSD or MDMA alongside therapy.
WatchERPPAD; MAP VETS.
Getting proven medicines to people
23.8% heavy drinking days at 3 monthsDetails and 1 trialsHide
Starting naltrexone in hospitals and emergency rooms, where many people with AUD are seen.
WatchYale ED trial.
Other new targets
Details and 3 trialsHide
CBD, apremilast, sleep drugs and anti-inflammatory approaches; results so far are mixed.
WatchColorado CBD trial.
Borrowed from other conditions
From Diabetes and obesity
Semaglutide
Phase 3
A GLP-1 drug that reduced heavy drinking days in randomized trials.
From Psoriasis
Apremilast
Phase 2
An oral anti-inflammatory approved for psoriasis, tested for alcohol craving.
From Insomnia
Suvorexant
Phase 2
A sleep medicine that blocks orexin, tested for sleep and drinking in AUD.
Open to join now
-
Moderate to severe AUD
Brenipatide
Locations and eligibility → -
AUD
Brenipatide
Locations and eligibility → -
Veterans with moderate to severe AUD
Semaglutide
Locations and eligibility → -
AUD
Cannabidiol (CBD)
Locations and eligibility → -
AUD with depression
Psilocybin
Locations and eligibility →
See every recruiting Alcohol use disorder trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Review finds early benefit for psilocybin therapy
J Psychopharmacol.
Oral semaglutide reduces heavy drinking days
Am J Psychiatry.
Semaglutide cuts heavy drinking in AUD with obesity
The Lancet.
Standard treatment today
- Mild or risky drinkingBrief advice and counseling; apps and online programs.
- Moderate to severeNaltrexone (pill or monthly shot) or acamprosate, with counseling or mutual-help groups; topiramate or gabapentin off-label.
- WithdrawalMedically supervised withdrawal, usually with benzodiazepines or phenobarbital.
- With liver diseaseAcamprosate or baclofen are often preferred; AUD treatment lowers relapse after liver injury.
- With PTSD or depressionTreating both together; trials of prazosin, suvorexant and psychedelic-assisted therapy.
How to read this page, and sourcesHow to read this page, and sources
- Stopping heavy drinking suddenly can cause dangerous withdrawal; talk to a doctor before stopping.
- If you need help now, the SAMHSA National Helpline (1-800-662-4357) is free and confidential.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Alcohol use disorder trials recruiting now →